
The US Federal Trade Commission (FTC) urged a US appeals court to reconsider an August 11 ruling that threw out antitrust claims against chipmaker Qualcomm, reported Bloomberg Law.
The three-judge panel erred when it ruled Qualcomm’s “no license no chips” policy didn’t result in an unfair surcharge on its competitors, the trade agency claimed on Friday, September 25, in a petition with the Ninth US Circuit Court of Appeals in San Francisco.
“The panel’s decision blesses the continued stifling of competition in multi-billion-dollar markets for cellular-communications chips on which much of the digital economy depends,” the agency stated in the petition. The FTC is asking that the case be heard before all active judges on the court.
The antitrust case, which the FTC had won at the trial level, threatened to undermine Qualcomm’s business model. The company gets the bulk of its revenue from selling chips, but the majority of its profit from licensing the thousands of patents it owns on technology that underpins how modern phone systems work.
Rehearing requests are rarely granted, but the FTC’s decision to push the issue keeps a cloud over Qualcomm that investors thought was over.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
CMA Investigates Aviva’s £3.6B Acquisition of Direct Line Group
May 14, 2025 by
CPI
Google Urges Texas Judge to Disregard Virginia Antitrust Ruling
May 14, 2025 by
CPI
Anthropic Ordered to Respond After AI Allegedly Fabricates Citation in Legal Filing
May 14, 2025 by
CPI
Rumble Adds David Boies to Legal Team in $2 Billion Antitrust Battle with Google
May 14, 2025 by
CPI
China Summons Delivery Giants Over Unfair Competition Concerns
May 13, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas